In March 2017, Medicinal Organic Cannabis Australia (MOCA) Pty Ltd began operations, with a focus on producing high-quality medicinal cannabis products. The company was incorporated in June of the same year, with headquarters based in Australia.

By December 2018, MOCA had become a fully licensed medicinal cannabis company in Sydney, Australia. This led to the company being awarded import and export cannabis licenses from the Australian government, as well as a License to Supply by Wholesale Poisons and/or Restricted Substances for Therapeutic Use and a License to Supply Drugs of Addiction from the NSW government.

Building on this success, MOCA it commenced importation of medical cannabis products into Australia.

In May 2019, MOCA developed a consortium for Italian cultivators of hemp, collaborating with State Governments to work with the European Union for funding. By August 2020, the company had established a research and cultivation facility in Italy.

Fast forward to October 2021, and MOCA proudly announced that it had harvested its first crop of CBD and CBG in its Italian facility. The company has demonstrated a clear commitment to producing high-quality medicinal cannabis products and expanding its operations on an international scale.

In March 2022, MOCA Health was established, a natural health clinic focusing on telehealth and medical cannabis medicines. This venture further solidifies the company's commitment to providing innovative solutions to support the health and well-being of its clients.

For potential investors, MOCA represents a promising opportunity to invest in a rapidly growing industry that is poised for success. The company's focus on high-quality products, commitment to innovation, and international expansion efforts make it an attractive option for those looking to invest in the medicinal cannabis market.